340B Drug Pricing Program
The AHA Aug. 26 urged the Centers for Medicare & Medicaid Services not to finalize two proposals in the calendar year 2027 outpatient prospective payment system proposed rule, warning that the policies suffer from “serious legal defects and substantial policy shortcomings” and would place…
The AHA Aug. 26 urged the Centers for Medicare & Medicaid Services not to finalize two proposals in the calendar year 2027 outpatient prospective payment system proposed rule,
AHA comments on two aspects of the Centers for Medicare & Medicaid Services’ (CMS) 2027 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Rule.
The AHA Aug. 25 submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act), a legislative discussion draft that would make significant changes to the current structure and scope of the 340B program.
AHA provides feedback on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act) discussion draft.
The AHA today submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act).
Reminder: Submit comments on calendar year 2027 outpatient prospective payment system proposed rule by Aug. 31.
The AHA's principal recommendation is that CMS use its authority to require drug manufacturers to make the Maximum Fair Price (MFP) available through a prospective, point-of-sale mechanism and eliminate any option that would permit manufacturers to satisfy their obligations through retrospective…
The AHA Aug. 12 at 3 p.m. ET will host a call for 340B hospitals to discuss several aspects of the 340B Drug Pricing Program, including the rebate model and congressional activities.
On Jan. 15, Eli Lilly & Company (Lilly) announced that starting Feb. 1 it will require all 340B covered entities to submit claims-level data (CLD) for all dispenses of Lilly drugs, regardless of setting.